Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients
Alexander Scheiter(University of Regensburg), Kirsten Utpatel(University of Regensburg), Anja Troeger(University Hospital Regensburg), Anja M. Sedlmeier(University Hospital Regensburg), Hauke Christian Tews(University Hospital Regensburg), Felix Steger, Marco J. Schnabel(University of Regensburg), Elisabeth Bumes(University Hospital Regensburg), Kristina Wohlfart(University Hospital Regensburg), Konstantin Drexler(University Hospital Regensburg), B. Zwicker(University Hospital Regensburg), Florian Lüke(University Hospital Regensburg), Daniela Hirsch(OTH Regensburg), Till Kaltofen(University Hospital Regensburg), S. Haferkamp(University Hospital Regensburg), Alexander Immel(University Hospital Regensburg), Sabine Einhell(University of Regensburg), Julia Maurer(University Hospital Regensburg), Ulrich Kaiser(University of Applied Sciences Landshut), Christina Brummer(University Hospital Regensburg), Frederik Hierl(University of Regensburg), Tobias Pukrop(University Hospital Regensburg), Diego F. Calvisi(University of Regensburg), Sophie Schlosser-Hupf(University Hospital Regensburg), Matthias Grube(University of Regensburg), Davor Lessel(University Hospital Regensburg), S. A. Klemm(University of Regensburg), Stephan Seitz(University Hospital Regensburg), Ramona Erber(University of Regensburg), Arne Kandulski(University Hospital Regensburg), Felix Keil(University of Regensburg), Markus Perl(University Hospital Regensburg), Elena Lüftl(University of Regensburg), Tom Schneider(University of Regensburg), Matthias Evert(University of Regensburg), Elena Wutzlhofer(University of Regensburg), Margit Klier-Richter(University of Regensburg), Christian Schulz(University Hospital Regensburg), Simon Mellin(University of Regensburg), W Dietmaier(University of Regensburg), Johannes Meier(University Hospital Regensburg), Daniel Heudobler(University of California San Diego)
Cited by 2
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC
|Gastroenterology|2006|726